Insight Molecular Diagnostics Inc. Impairment of Intangible Assets, Finite-lived
Insight Molecular Diagnostics Inc. (IMDX) reported Impairment of Intangible Assets, Finite-lived of $14.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2026-03-26
- Insight Molecular Diagnostics Inc. impairment of intangible assets, finite-lived for the quarter ending 2025-12-31 was $14.60M.
- Insight Molecular Diagnostics Inc. impairment of intangible assets, finite-lived for the quarter ending 2025-09-30 was $0.00.
- Insight Molecular Diagnostics Inc. impairment of intangible assets, finite-lived for the quarter ending 2023-12-31 was -$4.00K.
- Insight Molecular Diagnostics Inc. impairment of intangible assets, finite-lived for the quarter ending 2023-09-30 was $1.81M.
- Insight Molecular Diagnostics Inc. impairment of intangible assets, finite-lived for fiscal 2025 was $14.60M, a 65.16% decline from fiscal 2024.
- Insight Molecular Diagnostics Inc. impairment of intangible assets, finite-lived for fiscal 2024 was $41.90M, a 520.10% increase from fiscal 2023.
- Insight Molecular Diagnostics Inc. impairment of intangible assets, finite-lived for fiscal 2023 was $6.76M.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|---|
| 2025-12-31 | $14.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $14.60M derived: sum of 2 quarters · filed 2026-03-26 | $14.60M 10-K · filed 2026-03-26 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-11 | |||
| 2024-12-31 | $41.90M 10-K · filed 2026-03-26 | |||
| 2023-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $1.81M derived: sum of 2 quarters · filed 2025-03-24 | $1.81M derived: sum of 3 quarters · filed 2025-03-24 | $6.76M 10-K · filed 2025-03-24 |
| 2023-09-30 | $1.81M 10-Q · filed 2024-11-12 | $1.81M derived: sum of 2 quarters · filed 2024-11-12 | $6.76M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $4.95M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $4.95M 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |